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Abstract
Bone loss occurs when the cellular events of bone formation are quantitatively larger than
bone formation. This manuscript discusses the measurement of bone loss, occurrence in the
population, risk factors and consequences of bone loss. Recent developments in bone mass
measurement and biomarkers have improved our ability to assess bone loss. This process is
a normal concomitant of ageing. There are a number of other risk factors, including sex
hormone deficiency, physical inactivity, calcium/vitamin D deficiency, inflammatory arthritis,
corticosteroids, smoking and alcohol. The major consequence of bone loss in our ageing
society is fracture.
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Introduction
Bone is a highly metabolically active tissue; remodelling
continues throughout life. The remodelling process is an
active coupling of the processes of bone formation and
resorption. An imbalance in this active coupling phenome-
non, in which the cellular events of bone resorption are
quantitatively larger than bone formation, leads to bone loss.
The epidemiology of osteoporosis is distinct from that of
bone loss. Although excessive bone loss during ageing is
likely to contribute to the incidence of osteoporosis,
patients with fractures do not consistently have more rapid
bone loss, greater bone resorption or a lower rate of bone
formation. Any unifying hypothesis on the epidemiology of
osteoporosis needs to consider the relative contributions
of low peak bone density and bone loss to the deficit in
bone density in adulthood.
Assessment of bone loss
Bone mass can be determined in the total skeleton or in
local parts of the skeleton, such as the spine, hip and
forearm. Current methods for evaluating skeletal status,
assessing osteoporosis and bone loss and determining
fracture risk rely mostly on the non-invasive assessment of
bone mineral content and bone mineral density. The diag-
nostic procedure is complicated by the fact that different
body sites contain different ratios of trabecular to cortical
bone, which have different rates of loss. Furthermore, the
measurement of bone mass at one site (such as the
radius) might not accurately estimate the bone mass at
another site (such as the spine or hip), although there is
clearly correlation between sites.
A repeat bone mass measurement can be used to assess
bone loss. It is important to understand the limitations ofArthritis Research    Vol 2 No 6 Hunter and Sambrook
these methods. Most studies on involutional bone loss
have used absorptiometric techniques such as single
photon absorptiometry, dual photon absorptiometry and,
more recently, dual X-ray absorptiometry and single X-ray
absorptiometry. Most of these techniques adjust the esti-
mate of bone mineral for the errors in accuracy, which
arise from variability in fat mass between individuals. It is
likely that such errors of accuracy contribute to errors in
the estimation of bone mass. Moreover, variable fat
content of the spine with age is likely to contribute to
errors in the estimation of bone loss [1]. At the spine the
problem is compounded by the increasing prevalence of
osteoarthritis and vascular calcification at the lumbar
spine with age.
A further problem is that neither single nor dual X-ray
absorptiometry measures true bone density (g/cm3). The
areal bone density (g/cm or g/cm2) that they provide
yields an overestimate of volumetric bone mineral density.
This inaccuracy is negligible in the short term but is more
important in longitudinal studies, particularly as the width
of many bones can increase with age [2]. A recent study
by Grampp et al [3] advocated the use of quantitative
computed tomography as the most accurate method of
assessing bone loss.
Another approach to the estimation of the rate of loss has
been the measurement of biochemical markers of bone
turnover. Previous reports concerning the association of
markers with bone loss have been inconsistent. Some
cross-sectional studies have found that there is a weak
inverse relationship between biochemical markers and
bone density, and that marker levels are elevated during
periods of accelerated bone loss, such as early
menopause [4,5]. Several algorithms have been devel-
oped from longitudinal data to provide an estimate of bone
loss and stratify people into categories on the basis of
their rate of bone loss [6,7]. The large day-to-day varia-
tions in the concentration of biochemical markers, and het-
erogeneity in biochemical markers of bone turnover in
patients with fractures, make the application of these tech-
niques difficult even for longitudinal data. More work is
required to stratify further the risk of bone loss, but at
present the use of biochemical markers has limited value
in predicting bone loss in individuals [8].
Occurrence of bone loss
Bone loss is a normal concomitant of ageing and occurs
in both genders after peak bone mass has been attained
[9]. Starting from the middle of the third decade, women
lose 35% of their cortical bone and 50% of their trabecu-
lar bone [10], whereas men lose approximately two thirds
of this amount over their respective lifetimes [11].
Type 1 (postmenopausal) osteoporosis generally occurs
before the age of 65. It affects 5–25% of women in early
menopause [10,12]. Eastell et al [13] found that the ratio
of trabecular to cortical bone of the vertebral body was
75:25, whereas other investigators found the ratio in the
femoral neck to be 30:70 [14]. As trabecular bone loss is
accelerated relative to cortical bone loss after menopause,
regions with substantial amounts of trabecular bone might
become fragile sooner.
Type 2 osteoporosis occurs in both men and women and
involves the loss of both trabecular and cortical bone. The
prevalence of this type of bone loss is universal after peak
bone mass has been attained.
Studies have shown that from age 30–40, bone loss (both
trabecular and cortical) begins [10,11] and that
menopause is followed by an immediate decrease in bone
mass and density within a year at both peripheral and
central sites. The increased rate of bone loss reaches
equilibrium approximately 10 years after menopause and
then merges into a continuous age-related loss of predom-
inantly cortical bone [15].
There is no firm evidence that bone loss is a bimodal
process (in other words that there are fast losers and slow
losers). Some studies have stratified their analysis of frac-
ture risk into those who are fast, normal and slow bone
losers. The results of this analysis indicate that those with
a faster rate of bone loss have a higher future risk of frac-
ture [16].
Risk factors for bone loss
In contrast with the total variance in bone density, which is
undoubtedly predominantly genetic [17], studies on the
genetic determinants of bone loss have yielded conflicting
results [18–20]. From these data the view has emerged
that environmental factors such as exercise might exert a
large influence on bone loss at skeletal sites such as the
hip and wrist, whereas genetic factors might be important
in determining spinal bone loss. Gene–environment inter-
actions undoubtedly contribute at all sites of bone loss.
Of the many factors that influence bone loss, sex hormone
deficiency is by far the most important. Data from several
studies have shown that rapid bone loss in women after
the menopause can be effectively prevented by hormone
replacement therapy [21]. As well as sex hormones,
abnormalities of the calciotropic hormones are associated
with bone loss [22].
Distinct from the accelerated phase of postmenopausal
bone loss is a continuous and more gradual process of age-
related bone loss that starts before the menopause in
women and continues throughout life in both sexes [11].
This type of loss was previously considered to be a relatively
slow and constant process, but longitudinal prospective
research has provided evidence for a phase of acceleratedhttp://arthritis-research.com/content/2/6/441
bone loss in old age, affecting mainly the hip [23,24]. It is
difficult to differentiate the relative contributions of age and
oestrogen deficiency in most patients [25].
There have been few longitudinal studies investigating the
effect of physical activity on bone loss. Some studies have
shown beneficial effects of exercise on bone mass in post-
menopausal women. A recent longitudinal study provided
evidence that a physically active lifestyle in the later
decades of life can retard proximal femur loss [26]. This
suggested an interaction between physical activity,
weight, weight change and age-related bone loss. Under-
lying the idea that physical activity increases muscle
strength and hence bone mass, several studies have
examined the mechanical influence on bone loss [27].
Calcium intake has a significant effect on bone loss in
women although the magnitude of effect seems to be
dependent on age and site [28]. There is evidence that
calcium supplementation slows the rate of bone loss in
postmenopausal women [29], especially in those with a
low dietary intake of calcium [30]. Moreover, the supple-
mentation of calcium and vitamin D has been shown to
reduce the risk of hip fracture in institutionalized elderly
patients, who might be deficient in these nutrients [31].
The osteoporosis associated with inflammatory diseases
such as rheumatoid arthritis and neoplastic diseases such
as myeloma is due in large part to increased bone loss.
This has been extensively documented in rheumatoid arthri-
tis, where there is evidence of systemic and periarticular
bone loss at an early phase in the disease [32]. Cortico-
steroids also cause osteoporosis by inducing accelerated
bone loss [33].
Smoking predisposes to osteoporosis by inducing an
earlier menopause and by causing an increased metabolic
breakdown of oestrogen, both of which tend to accelerate
bone loss [34].
High intakes of alcohol are known to have deleterious
effects on bone mass, owing to the inhibitory effect of the
alcohol on osteoblastic activity and the fact that the indi-
viduals who consume large amounts of alcohol are also
prone to protein and/or calcium malnutrition, reduced
mobility and hypogonadism.
Higher weight is associated with lower rates of bone loss
[26]; conversely, older women with a smaller body size
are at increased risk of hip fracture [35]. This increased
risk is seen predominantly in those with involuntary weight
loss [36].
Other risk factors for bone loss include gastrointestinal disor-
ders causing malabsorption, the use of drugs such as anti-
convulsants, chronic renal disease and amenorrhoea [37].
Outcome of bone loss: clinical implications
The major consequence of bone loss in our ageing society
is fracture. The relative contributions of peak bone mass
and bone loss to the development of low bone mass later
in life with its attendant fractures requires clarification.
Until these factors can be measured and their contribu-
tions to fracture development calculated it will be difficult
to determine the exact role of bone loss in fracture devel-
opment, because other factors associated with bone loss
such as the development of microarchitectural abnormali-
ties and microdamage could also be contributing.
Bone density decreases with advancing age as a result of
bone loss [11]. Prospective epidemiological studies indi-
cate that bone mineral density is the single best predictor
of fractures [38,39]. A 1 SD decrease in bone mass can
account for a 50–100% increase in the risk of all non-
spine fractures, and a 1 SD difference in bone mass in the
femoral neck is associated with a relative risk of 2.6 for
subsequent hip fracture.
Bone turnover is difficult to interpret on an individual level.
Heterogeneity in histomorphometric parameters of bone
turnover, and biochemical markers of bone turnover [40],
are found in patients with fractures. Eriksen et al [41]
showed that patients with vertebral fractures had increased
bone resorption and decreased bone formation at the cel-
lular level but not at the tissue level. Meunier et al [42]
found that approximately 50% of patients with vertebral
fractures had no evidence of abnormalities in bone resorp-
tion or formation, approximately 30% had higher bone
resorption surfaces, and approximately 20% had evidence
of decreased formation.
Approximately 40 in 100 women will experience one or
more fractures after the age of 50 years. At 50 years for
women the lifetime risk is 17.5% for hip fracture, 16% for
vertebral fracture and 16% for Colles’ fracture; for men,
the respective lifetime risks are 6%, 5% and 2.5% [43].
The consequences of these fractures, which can include
reduced life expectancy, prolonged medical care and loss
of independence, have a profound socioeconomic impact
in an ageing population [44]. The different fracture risk in
men is a result of a number of contributing factors, includ-
ing less bone loss with ageing [45].
Management of bone loss
The two approaches that can be adopted in bone loss
modification are, firstly, to identify those at greatest risk
and, secondly, to move the distribution of bone loss for the
whole population. From the viewpoint of the individual
patient, bone loss is only one of the factors associated
with ageing that contributes to fracture risk; management
therefore needs to be individualized. Initially addressing
their modifiable risk factors remains the gold standard of
current medical practice. Following this pharmacologicalintervention might be required for those individuals identi-
fied as being ‘at risk’.
No discussion of epidemiology would be complete without
considering the pharmaco-epidemiology of bone loss. In
recent years a plethora of antiresorptive agents have
become available. Rather than identify their individual
strengths on the modification of bone loss, we would
encourage readers to consider the various consensus
statements available [46].
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